MD05

Identification

Generic Name
MD05
DrugBank Accession Number
DB06375
Background

MD05 is a beta-tricalcium phosphate (beta-TCP) coated with recombinant human growth/differentiation factor-5 (rhGDF-5).

Type
Small Molecule
Groups
Investigational
Synonyms
Not Available
External IDs
  • MD 05
  • MD-05
  • MD05

Pharmacology

Indication

Investigated for use/treatment in periodontal disease.

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action

MD05 has two components: the recombinant growth factor, rhGDF-5, a naturally occurring human protein that acts by promoting the growth of bone and the inorganic carrier, beta-Tricalcium phosphate (beta-TCP). Beta-TCP is a synthetic calcium phosphate biomaterial, which acts as a scaffold and space maintainer for new bone ingrowth. It is a well accepted biomaterial for bone augmentation in dentistry and orthopaedic surgery such as e.g. spinal fusion. Growth factor and carrier material are combined by Scil’s proprietary technology, which allows for a homogeneous distribution of the growth factor on the carrier and maintenance of structure and function of the protein and avoidance of its aggregation.

Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Categories

Drug Categories
Not Available
Classification
Not classified
Affected organisms
Not Available

Chemical Identifiers

UNII
Not Available
CAS number
Not Available
InChI Key
Not Available
InChI
Not Available
IUPAC Name
Not Available
SMILES
Not Available

References

General References
Not Available
Not Available

Clinical Trials

Clinical Trials
Clinical Trial & Rare Diseases Add-on Data Package
Explore 4,000+ rare diseases, orphan drugs & condition pairs, clinical trial why stopped data, & more. Preview package
PhaseStatusPurposeConditionsCountStart DateWhy Stopped100+ additional columns
2Unknown StatusTreatmentAugmentation, Alveolar Ridge1somestatusstop reasonjust information to hide
2Unknown StatusTreatmentBone Loss, Alveolar / Periodontal Bone Loss1somestatusstop reasonjust information to hide

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
Not Available
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available
Chromatographic Properties
Collision Cross Sections (CCS)
Not Available

Drug created at March 19, 2008 16:28 / Updated at August 16, 2024 10:59